[go: up one dir, main page]

WO2019078662A2 - Inhibition de la tyrosinase et activité de blanchiment de la peau d'extrait de solvant de desmodium sequax ou fraction de celui-ci - Google Patents

Inhibition de la tyrosinase et activité de blanchiment de la peau d'extrait de solvant de desmodium sequax ou fraction de celui-ci Download PDF

Info

Publication number
WO2019078662A2
WO2019078662A2 PCT/KR2018/012390 KR2018012390W WO2019078662A2 WO 2019078662 A2 WO2019078662 A2 WO 2019078662A2 KR 2018012390 W KR2018012390 W KR 2018012390W WO 2019078662 A2 WO2019078662 A2 WO 2019078662A2
Authority
WO
WIPO (PCT)
Prior art keywords
extract
fraction
desmodur
present
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/012390
Other languages
English (en)
Korean (ko)
Other versions
WO2019078662A3 (fr
Inventor
손광희
박호용
박정광
엄상미
응우엔반씽
이민지
이창영
조한영
최상호
트란더바이트
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2019078662A2 publication Critical patent/WO2019078662A2/fr
Publication of WO2019078662A3 publication Critical patent/WO2019078662A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a process for the preparation of Desmodium sequax wall extract or fractions thereof as an active ingredient, or a composition for preventing or treating dermatological pigmentary diseases.
  • the skin color of a person is genetically determined by the concentration and distribution of melanin in the skin, but is also influenced by environmental or physiological conditions such as sunlight, fatigue, and stress.
  • melanogenesis which determines the color of skin
  • Melanocytes which are melanocytes, secrete cells from ultraviolet light in melanosomes called intracellular organelles It is known that the melanin is transferred from melanocytes to keratinocytes. It has been reported that melanin transferred to keratinocytes determines skin color.
  • the precursor required for the melanin biosynthesis process is an amino acid called tyrosine.
  • the tyrosine is converted into dihydroxyphenylalanine (DOPA), and then converted to melanin through a substance called dopaquinone .
  • DOPA dihydroxyphenylalanine
  • melanogenesis enzymes include tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1) and tyrosinase-related protein 2 -2 / DOPA, chrome tautomerase), and the melanin-forming enzyme is known to be regulated by a transcription factor called MITF (microphthalmia-associated transcription factor).
  • Tyrosinase which plays an important role in the melanin synthesis pathway, converts L-tyrosine to L-DOPA (L-3,4-dihydroxyphenylalanine), rapidly converts the resulting L-DOPA to L-dopaquinone,
  • the melanin is formed by various reactions of the melanin.
  • Melanin synthesized by tyrosinase makes the skin darker. Studies on skin whitening method to suppress skin melanin synthesis and brighten skin color due to health or cosmetic demand are actively under way.
  • arbutin of inhibiting tyrosinase activity As commonly known as whitening components, arbutin of inhibiting tyrosinase activity, kojic acid (kojic acid), azelaic acid, aloe sour 4-butyl resorcinol, resveratrol, ceramides, seuping High-1-phosphate, seuping tympanic Force A substance such as polyquinoline, hydroquinone (Korean Patent Laid-Open Publication No. 2016-0014271), and the like.
  • Such whitening ingredients are possible skin gwasaek small improvement in the chimchakjeung by inhibiting the synthesis of melanin, lightening the skin tone to achieve a skin-lightening or ultraviolet light, hormones, or the spots or freckles due to the dielectric and the like.
  • some of the whitening ingredients have a problem in that when the skin is applied, the use amount is limited due to safety problems such as irritation and redness, or the effect is insignificant so that a substantial effect can not be expected.
  • hydroquinone if the rain has been banned its use as an unwanted side effect replaced by the (European Committee 24 th Dir 2000/ 6 / EC), hydroquinone arbutin structural analogs, such as bars, such as irreversible bleaching.
  • One object of the present invention is to provide a desmodium sequax wall extract or a fraction thereof as an active ingredient.
  • Another object of the present invention is to provide a health functional food for skin whitening comprising Desmoditic sputum extract or a fraction thereof as an active ingredient.
  • It is a further object of the present invention to provide a skin whitening method comprising the step of administering a desmodur spsculus extract or a fraction thereof to a subject.
  • composition of the present invention not only has a tyrosinase inhibitory effect and a melanin formation inhibitory effect but also has stability and can be safely and usefully used as a whitening composition or a therapeutic composition for skin hypercholesterolemia.
  • Figure 1 shows the tyrosinase inhibitory activity of the natural extract SD018 in the present invention.
  • Fig. 2 shows that the active fraction of the SD018 natural extract of the present invention is obtained by silica column chromatography.
  • FIG. 3 shows a pixel analysis for analyzing the inhibitory effect of melanin on the zebrafish embryo of the natural extract SD018 in the present invention.
  • FIG. 4 shows the inhibitory effect on melanin formation by zebrafish embryo of the natural extract SD018 in the present invention.
  • FIG. 5 shows the effect of inhibiting melanin formation by zebrafish fry of natural extract SD018 in the present invention.
  • the present invention relates to a method for producing a desmodium sequax Wall extract or a fraction thereof as an active ingredient.
  • desmodium in the present invention is a genus belonging to the genus Fabaceae and distributed in the tropical and subtropical regions. Desmodium ( Desmodium) There are about 350 species including sequax . Mainly inconspicuous leguminous plants with bright colors and large flowers, used as green fertilizer, feed and some herbs.
  • the extract of Desmodur spscus herein comprises extracts of all the formulations which can be formed using extracts of the Desmodur spsculus extract of the present invention and its diluted solution, concentrate, dried product, adjusted product, purified product or mixture thereof.
  • Desmodur spsculus extract may be produced by extracting from at least one of roots, stems, leaves or flowers of Desmodur spsc, but is not particularly limited thereto.
  • Desmodurium spuxus extract of the present invention can be obtained from Desmodiums sp.
  • These methods may be performed alone or in combination of two or more methods.
  • the kind of the extraction solvent used in the extraction of the present invention is not particularly limited, and any solvent known in the art can be used.
  • Non-limiting examples of the extraction solvent of the present invention include water, a C1-4 alcohol, hexane, ethyl acetate, chloroform, dichloromethane and mixtures thereof And a solvent to be selected.
  • fraction refers to the result obtained by performing a fractionation to separate a specific component or a specific component group from a mixture containing various components.
  • the fractionation method for obtaining the fractions of the present invention is not particularly limited and may be carried out according to a method commonly used in the art.
  • a solvent fractionation method performed by treating various solvents an ultrafiltration fractionation method performed by passing through an ultrafiltration membrane having a constant molecular weight cut-off value, various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity ), A combination thereof, and the like.
  • the kind of the fraction solvent used to obtain the fraction of the present invention is not particularly limited, and any solvent known in the art can be used.
  • Non-limiting examples of the fraction solvents herein include polar solvents such as water, alcohols (e.g., 1 to 4 carbon atoms); And non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of one or more.
  • the extract or fraction of Desmodur squash of the present invention is generally selected from the range of 0.000001 to 0.1 part by weight per 100 parts by weight based on the total weight of the composition of the present invention, but is not particularly limited thereto.
  • compositions herein may inhibit tyrosinase activity and / or inhibit melanin synthesis.
  • skin whitening in the present invention refers to brightening skin tone by inhibiting the synthesis of melanin pigment and / or inhibiting tyrosinase activity.
  • the skin whitening may also include improving skin hyperpigmentation, such as sunburn, freckles, blotchiness, or melanoma due to ultraviolet light, hormones or heredity.
  • the cosmetic composition of the present invention may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, spray, And may be formulated and provided in a selected form.
  • the cosmetic composition of the present application may further comprise a cosmetically acceptable carrier.
  • the kind of the cosmetically acceptable carrier of the present invention is not particularly limited so long as it does not impair the activity and properties of the cosmetic composition of the present invention, and any cosmetically acceptable carrier conventionally used in the art can be used.
  • Non-limiting examples of the cosmetically acceptable carrier include saline, sterilized water, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more.
  • the cosmetically acceptable carriers herein may comprise non-naturally occuring carriers.
  • the cosmetically acceptable carriers herein vary according to the formulation of the cosmetic composition.
  • the formulation of the cosmetic composition of the present invention is a paste, cream or gel
  • an animal oil a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide May be used, but is not limited thereto.
  • lactose When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or the like may be used as a carrier component. But are not limited to, propellants such as hydrocarbons, propane / butane or dimethyl ether.
  • a solvent, a dissolving agent or an emulsifying agent may be used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, Propylene glycol, 1,3-butyl glycol oil and the like can be used.
  • an oil such as cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or sorbitan Fatty acid esters can be used, but are not limited thereto.
  • the formulation of the cosmetic composition of the present invention is a suspension
  • a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, but are not limited thereto.
  • the formulation of the cosmetic composition of the present invention is a soap
  • the formulation of the cosmetic composition of the present invention is a pack, a fill-off pack containing polyvinyl alcohol or the like, a wash-off pack containing a pigment such as kaolin, talc, zinc oxide, , Or a mask sheet pack, and is not particularly limited thereto.
  • the cosmetic composition of the present invention may further comprise components included in conventional skin external agent components such as water, a surfactant, a moisturizer, a lower alcohol, a chelating agent, a bactericide, an antioxidant, an antiseptic, a pigment and a fragrance.
  • conventional skin external agent components such as water, a surfactant, a moisturizer, a lower alcohol, a chelating agent, a bactericide, an antioxidant, an antiseptic, a pigment and a fragrance.
  • Another aspect of the present invention is to provide a health functional food for skin whitening, which comprises Desmodur spsculus extract or a fraction thereof as an active ingredient.
  • Desmodur spsculus extract or its fractions and whitening are as described above.
  • health functional food in the present invention refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings using raw materials and components having useful functions in the human body.
  • the term "functional" as used herein means that the structure and function of the human body have a beneficial effect on health uses such as controlling nutrients or physiological actions.
  • the health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art.
  • the formulation of the dietary supplement is also formulated to be recognized as a dietary supplement can be made without limitation.
  • the health functional food of the present invention can be manufactured in various formulations, and unlike general pharmaceuticals, it has advantages in that it does not have side effects that may occur when a food is used as a raw material for a long period of time, and has excellent portability. of health food can be consumed as a supplement for enhancing the skin whitening effect.
  • the health functional food of the present invention may contain various flavors or natural carbohydrates as an additional ingredient.
  • the above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol.
  • sweeteners include natural sweeteners such as tau Martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.
  • the health functional food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, protective colloid thickener, pH adjuster, stabilizer, preservative, glycerin, A carbonating agent used in a carbonated beverage, and the like. These components may be used independently or in combination. Although the proportion of such additives is not critical, it is generally selected from the range of 0.000001 to 0.1 part by weight per 100 parts by weight of the health food of the present invention, but is not particularly limited thereto.
  • Another aspect of the present invention is to provide a pharmaceutical composition for preventing or treating dermatological pigmentary diseases, which comprises Desmodur spsculus extract or a fraction thereof as an active ingredient.
  • Desmodur spsculus extract or its fractions are as described above.
  • dermatological pigmentary disease in the present invention means a disease in which a coloring matter is excessively deposited on the skin.
  • the dermatological pigmentation disease can be spots, freckles, black spots, dull spots or melanomas.
  • prevention in the present invention means any action by which the composition of the present invention inhibits or delays the development of dermatological pigmentary diseases.
  • treatment in the present invention means any action which causes the pharmaceutical composition of the present invention to improve or alleviate the symptoms of dermatological pigmentary diseases.
  • the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier in the present invention refers to a carrier or diluent which does not irritate the organism and does not inhibit the activity or properties of the dermatological pigment disease symptom of the present invention.
  • the pharmaceutical carrier which is acceptable for the composition to be formulated into a liquid solution include sterilization and sterilization which are suitable for a living body and include saline, sterilized water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol And one or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added.
  • pharmaceutically acceptable carriers of the present invention may include non-natural carrier.
  • compositions of the present invention may be administered in single or multiple doses in a pharmaceutically effective amount.
  • the term " pharmaceutically effective amount” means an amount sufficient to prevent or treat a disease at a reasonable benefit / risk ratio applicable to medical prophylaxis or treatment, and the effective dose level will depend on the severity of the disease, , The body weight of the patient, the health, the sex, the sensitivity of the patient to the drug, the time of administration of the composition of the present invention, the route of administration and the rate of release, the duration of the treatment, And other factors well known in the medical arts.
  • Another aspect of the present invention is to provide a quasi-drug composition for skin whitening, which comprises Desmodur spsculus extract or a fraction thereof as an active ingredient.
  • Desmodur spsculus extract or its fractions are as described above.
  • quasi-drug in the present invention refers to products which are used for diagnosis, treatment, improvement, alleviation, treatment or prevention of diseases of human beings or animals
  • Quasi-drugs are products that are used for the treatment and prevention of diseases of humans and animals, products that are mild or have no direct action on the human body.
  • the quasi-drug composition of the present invention can be manufactured in a form selected from the group consisting of a body cleanser, a foam, a soap, a mask, an ointment, a cream, a lotion, an essence and a spray, but is not limited thereto.
  • the desmodium spuxx extract of the present invention or a fraction thereof may be directly added, or may be used in combination with other quasi-drugs or quasi-drugs, Can be used.
  • the present invention provides a method for whitening skin comprising administering to the individual an extract of Desdodium sp., Or a fraction thereof.
  • the extract of Desdodium gratisurea or its fractions and whitening are as described above.
  • the extract or fraction thereof of Desmodur parchment herein may be administered to an individual in need thereof in an effective amount.
  • the level of effective dose can be determined by a person skilled in the art on the basis of common sense to the extent that the desired skin whitening effect is exhibited.
  • a method of preventing or treating a dermatological pigmentary disease comprising administering to a subject a desmodur spsculus extract or a fraction thereof.
  • the extract or fraction thereof of Desmodur parchment herein may be administered to an individual in need thereof in an effective amount.
  • the level of effective dose can be determined by those skilled in the art on the basis of common sense to the extent that the effect of preventing or treating dermatological pigment diseases is exhibited.
  • Desmodium sequax Wall was taken and dried at room temperature. The dried material was cut to a suitable size and pulverized using a blender mixer to obtain a pulverized material.
  • Desmodur spsculus extract (SD018) was obtained according to the solvent conditions as follows.
  • desmoduric sputum extract was prepared by dissolving L-tyrosine (Sigma) with L-DOPA (L-3,4 -dihydroxy phenylalanine. < / RTI >
  • tyrosinase inhibition assay for L-tyrosine 120 ⁇ l of 0.1 M sodium phosphate buffer solution (pH 6.5), 20 ⁇ l of 1,000 unit / mL tyrosinase, and 20 ⁇ l of sample were added to each well of a 96-well microplate and incubated at room temperature for 10 minutes After the reaction, 40 ⁇ l of 1.5 mM L-tyrosine was added, and the absorbance was measured at 490 nm for 10 minutes at 25 ° C.
  • N-control distilled water was used.
  • P-control positive control
  • kojic acid Sigma
  • SD018 was assayed at 20 to 80 ⁇ g / .
  • the tyrosinase activity of the positive control kojic acid (KA, Sigma) was 87.11 ⁇ 2.60% (KA20, KA 20 ⁇ M), 58.65 ⁇ 1.35% (KA40, KA 40 ⁇ M), 24.45 ⁇ (SD40, SD018 40 ⁇ g / mL), and 42.24 ⁇ 2.05% (SD80, SD018 80 ⁇ g, respectively) / mL).
  • KA positive control kojic acid
  • Example 2 To via a silica gel column chromatography to analyze the amount of weight under reduced pressure to concentrate the separated fraction following, Example 2 and tyrosinase inhibition in the same way effect, we analyzed the IC 50 value was diluted for each concentration of ( Table 2).
  • Zebra fish (Danio rerio) used as an experimental animal was cultivated in a fish tank with a temperature of 28-29 at a suitable growth temperature.
  • the zebrafish feed hatches the commercially available INVE artemia sycsts and brine shrimp, hatching 2-3 times a day, and the day and night cycle is controlled by the 10 hour cycle of 14 hours night .
  • To get a zebrafish embryo I put a pair of male and female into a special mating tub at 16-18 o'clock the previous day. In order to induce spawning, light was given the next morning to induce spawning to secure the embryo.
  • the collected embryos were transferred to a Petri dish and stored in 0.1% methylene blue solution to determine whether they were fertilized or not. Modified embryos not stained with methylene blue were selected and transferred to a zebrafish embryo culture medium containing 0.2 g / L sea salt (sigma). After the fertilization, the embryos generated at 9 hours were divided into three groups of negative embryos in each well of a 96-well microplate and divided into a negative control (NCtrl), a positive control (PCtrl) and an experimental group. The experiment was carried out in triplicate.
  • NCtrl negative control
  • PCtrl positive control
  • the positive control group was an embryo culture medium
  • the positive control group 1 was an embryo culture medium containing 0.2 mM 1-phenyl-2-thyourea (PTU, Sigma)
  • the positive control group 2 was an embryo culture medium containing 20 mM kojic acid (Sigma)
  • an embryo culture medium containing 20 mM arbutin (Sigma) and in Experiment Groups 1 and 2 were added with 200 ⁇ L / well of each embryo culture medium containing 100 to 200 mg / mL of each sample.
  • the embryonic developmental stages were observed during 9-57 hpf (hours post fertilization) using an Olympus SZ2-ILST (eXcope T1000 camera) stereomicroscope and an Optika XDS-2 (Optika 4083.13 HDMI Prof Camera) inverted microscope.
  • Olympus SZ2-ILST eXcope T1000 camera
  • Optika XDS-2 Optika 4083.13 HDMI Prof Camera
  • a drink comprising the above Desmodur spsculus extract or a fraction isolated therefrom was prepared as follows.
  • Emulsifier type cosmetics were prepared with the compositions shown in Table 3 below.
  • the manufacturing method is as follows.
  • step 2) was gradually added to the mixture of step 3), and the mixture was emulsified at 7,000 to 12,000 rpm for 2 to 3 minutes.
  • step 6) The mixture of step 6) was degassed after emulsification and cooled to 25-35 ° C to prepare an emulsifier-type cosmetic.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition cosmétique pour le blanchiment de la peau, un aliment diététique fonctionnel, une composition quasi-médicamenteuse, et une composition pharmaceutique pour la prévention ou le traitement des maladies de l'hyperpigmentation contenant un extrait de Desmodium sequax ou une fraction de celui-ci.
PCT/KR2018/012390 2017-10-19 2018-10-19 Inhibition de la tyrosinase et activité de blanchiment de la peau d'extrait de solvant de desmodium sequax ou fraction de celui-ci Ceased WO2019078662A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170136064A KR101971679B1 (ko) 2017-10-19 2017-10-19 데스모디움 스컥스(Desmodium sequax Wall) 용매 추출물 또는 이의 분획물의 티로시나아제 저해 및 미백활성
KR10-2017-0136064 2017-10-19

Publications (2)

Publication Number Publication Date
WO2019078662A2 true WO2019078662A2 (fr) 2019-04-25
WO2019078662A3 WO2019078662A3 (fr) 2019-06-06

Family

ID=66174604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012390 Ceased WO2019078662A2 (fr) 2017-10-19 2018-10-19 Inhibition de la tyrosinase et activité de blanchiment de la peau d'extrait de solvant de desmodium sequax ou fraction de celui-ci

Country Status (2)

Country Link
KR (1) KR101971679B1 (fr)
WO (1) WO2019078662A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102366234B1 (ko) * 2020-07-10 2022-02-23 한국생명공학연구원 데스모디움 스컥스(Desmodium sequax Wall) 유래의 피부 주름 개선효과를 보이는 용매 추출물 또는 이의 분획물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3487617B2 (ja) * 1993-09-14 2004-01-19 恒雄 難波 化粧料
JPH0812565A (ja) * 1994-06-29 1996-01-16 Shiseido Co Ltd 皮膚外用剤
JP2001316239A (ja) * 2000-05-10 2001-11-13 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
JP2004352659A (ja) * 2003-05-29 2004-12-16 Shiseido Co Ltd 美白用皮膚外用剤
CN103265493A (zh) * 2013-06-08 2013-08-28 贵州大学 波叶山蚂蝗提取物及提取方法和提取物的新用途
KR101761142B1 (ko) 2015-12-09 2017-07-25 (주)제주사랑농수산 애기수영 추출물을 이용한 피부 미백용 조성물
KR101906245B1 (ko) 2016-12-23 2018-10-10 강원대학교산학협력단 특정 발아 상태의 메밀 종자 추출물을 유효성분으로 포함하는 피부 미백 및 항산화용 화장료 조성물

Also Published As

Publication number Publication date
WO2019078662A3 (fr) 2019-06-06
KR101971679B1 (ko) 2019-04-23

Similar Documents

Publication Publication Date Title
WO2020060060A1 (fr) Composition cosmétique comprenant un extrait de racine adventive de centella asiatica en tant que principe actif pour le blanchiment de la peau et la réduction des rides
WO2020246766A1 (fr) Composition pour prévenir ou atténuer le vieillissement cutané, contenant un extrait de rhodiola sachalinensis fermenté à l'aide de bovista plumbea
KR101908077B1 (ko) 천연 한방 추출물을 유효성분으로 포함하는 미백, 피부 노화 방지 또는 피부 주름 개선용 조성물
KR101774867B1 (ko) 성숙한 잣구과 껍질 추출물을 유효성분으로 포함하는 미백 또는 모공수축용 화장료 조성물
WO2021215882A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un extrait de péricarpe de camélia en tant que principe actif
JP2003160461A (ja) 皮膚外用剤
KR101702441B1 (ko) 피부 미백용 조성물
KR20080104759A (ko) 산거울 추출물 또는 이로부터 분리된 알파-비니페린을유효성분으로 함유하는 피부 미백용 조성물
WO2019078662A2 (fr) Inhibition de la tyrosinase et activité de blanchiment de la peau d'extrait de solvant de desmodium sequax ou fraction de celui-ci
KR100894714B1 (ko) 피부 미백 및 항산화 활성을 가지는 백모사 추출물
KR101854766B1 (ko) 미백 효능을 갖는 트리히드록시 이소플라본 및 감초 추출물의 복합체
KR100742267B1 (ko) 서장채국화 추출물, 이의 제조 방법 및 이를 유효성분으로 함유하는 미백용 화장료 조성물
WO2024063587A1 (fr) Composition d'amélioration de la peau contenant, en tant que principe actif, un extrait de feuille d'eryobotrya japonica induisant une activité d'autophagie
KR101570123B1 (ko) 잣외종피 추출물을 유효성분으로 포함하는 화장료 조성물
WO2018021802A1 (fr) Composition permettant d'inhiber une sécrétion de sébum comprenant un extrait de germe de pêche
WO2020256380A1 (fr) Composition de blanchiment de la peau comprenant de la carvone ou un sel de celle-ci en tant que principe actif
KR102054132B1 (ko) 민물김 추출물을 유효성분으로 포함하는 피부 미백용 조성물
KR101774860B1 (ko) 잣외종피 추출물을 유효성분으로 포함하는, 미백 또는 모공수축용 화장료 조성물
WO2020256381A1 (fr) Composition de blanchiment de la peau comprenant en tant que principe actif de l'octadécène ou un sel de celui-ci
JP3647296B2 (ja) チロシナーゼ活性阻害およびこれを含有する組成物
WO2016003120A1 (fr) Composition de blanchiment comprenant un extrait de scutellaria alpina
WO2020241972A1 (fr) Composition cosmétique comprenant de la substance p pour le blanchiment de la peau
KR102435602B1 (ko) 알로에 베라 부정근 추출물을 함유하는 피부 개선용 화장료 조성물
WO2025116202A1 (fr) Composition anti-âge contenant un extrait d'écorce de mandarine satsuma non mûre
WO2025116201A1 (fr) Composition anti-âge contenant un extrait de pulpe de citron jeramon

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18867386

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18867386

Country of ref document: EP

Kind code of ref document: A2